Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
What techniques do you use to distinguish malignant from non-malignant (eg BPH etc) causes of PSA rise in patients with non-metastatic prostate cancer and a rising PSA in spite of ADT?
Related Questions
How would you treat a patient presenting with de novo metastatic prostate cancer and baseline low testosterone?
With multiple PARPi + ARSI combinations now approved, how are you selecting which combination to use for a patient with BRCA mutated mCRPC?
How would you approach treating a patient with prostate adenocarcinoma with urothelial features?
Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?
What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?
What is the minimum duration to be on bicalutamide prior to starting GnRH agonist in de novo metastatic prostate cancer with significant bone disease?
What dose of prednisone do you prefer when treating CRPC vs CSPC with abiraterone?
Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
